![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Windgap and its manufacturing partners are commercializing its ANDI® wet/dry autoinjector platforms. The first product using this platform will be epinephrine for the treatment of anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Taiwania Capital
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 07, 2021